MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$256,147K
Net Income
$42,987K
Net Profit Margin
16.78%
EPS
$0.36
Unit: Thousand (K) dollars
Revenue Breakdown
Hypercortisolism Products
Lifyorli
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Product revenue, net
256,147
164,903
202,125
207,638
Cost of sales
4,061
2,883
2,545
4,596
Research and development
53,890
66,265
64,856
68,846
Selling, general and administrative
156,896
145,356
130,237
123,977
Total operating expenses
214,847
214,504
197,638
197,419
Income (loss) from operations
41,300
-49,601
4,487
10,219
Interest and other income
4,631
4,886
5,423
5,024
Income before income taxes
45,931
-44,715
9,910
15,243
Income tax (expense) benefit
2,944
-12,954
-14,378
-4,425
Net income
42,987
-31,761
24,288
19,668
Basic EPS
0.4
-0.3
0.234
0.19
Diluted EPS
0.36
-0.3
0.202
0.16
Basic Average Shares
105,377,000
104,435,000
103,686,000
103,545,000
Diluted Average Shares
118,385,000
104,435,000
120,205,000
119,439,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Hypercortisolism Products
$208,583K
Lifyorli
$47,564K
Product revenue, net
$256,147K
(31.74%↑ Y/Y)
Income (loss) from
operations
$41,300K
(54.83%↑ Y/Y)
Interest and other income
$4,631K
(-7.69%↓ Y/Y)
Total operating
expenses
$214,847K
(28.07%↑ Y/Y)
Income before income
taxes
$45,931K
(44.93%↑ Y/Y)
Selling, general and
administrative
$156,896K
(51.08%↑ Y/Y)
Research and development
$53,890K
(-10.88%↓ Y/Y)
Cost of sales
$4,061K
(18.29%↑ Y/Y)
Net income
$42,987K
(22.30%↑ Y/Y)
Income tax (expense)
benefit
$2,944K
(185.16%↑ Y/Y)
Buy us a coffee
CORCEPT THERAPEUTICS INC (CORT)
CORCEPT THERAPEUTICS INC (CORT)